👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

J&J reaches opioid settlement with holdout U.S. state New Mexico

Published 01/14/2022, 04:33 PM
Updated 01/14/2022, 06:25 PM
© Reuters. FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange. REUTERS/Brendan McDermid
CAH
-
MCK
-
COR
-
JNJ
-

By Nate Raymond

(Reuters) -Johnson & Johnson on Friday said it had agreed to pay $44 million to resolve claims that it fueled the opioid epidemic in New Mexico, a state which originally opted against participating in a nationwide settlement resolving thousands of similar cases.

The New Brunswick (NYSE:BC), New Jersey-based drugmaker said the $44 million was consistent with the terms of a proposal for J&J (NYSE:JNJ) and drug distributors McKesson Corp (NYSE:MCK), AmerisourceBergen (NYSE:ABC) Corp and Cardinal Health Inc (NYSE:CAH) to pay up to $26 billion to resolve the cases nationally.

New Mexico Attorney General Hector Balderas, a Democrat, initially declined to take part in those settlements but last month said his state would participate in the distributors' $21 billion deal. He did not join J&J's $5 billion deal at that time.

Under Friday's accord, J&J agreed to pay New Mexico its share of the nationwide settlement in 2022, rather than over several years, if all of the state's local governments signed on by May 31.

"Opioids have destroyed families in New Mexico, and local communities and addiction professionals still need vital funding to save lives and fight this ongoing tragic epidemic," Balderas said in a statement.

J&J did not admit wrongdoing and in a statement said it appropriately marketed its pain medications.

More than 3,300 lawsuits, largely by state and local governments, are pending, seeking to hold those and other companies responsible for an opioid abuse crisis that has led to hundreds of thousands of overdose deaths.

How much of the $26 billion the companies ultimately must pay and how much outstanding litigation they will face depends on state and local government participation.

© Reuters. FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange. REUTERS/Brendan McDermid

Settlement supporters have extended https://www.reuters.com/legal/litigation/us-drug-distributors-extend-deadline-state-subdivisions-join-opioid-settlement-2021-12-22 to Jan. 26 a deadline for cities and counties in states that backed the proposal to opt-in to the deals, citing the potential for more states to join.

Nevada and Georgia agreed this month https://www.reuters.com/world/us/georgia-reverses-course-joins-26-billion-us-opioid-settlement-2022-01-07 to settle with the companies. Six states have not settled with some or all of the four companies.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.